Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview
- PMID: 35954310
- PMCID: PMC9367474
- DOI: 10.3390/cancers14153646
Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview
Abstract
Pineal region tumors are rare intracranial tumors, accounting for less than 1% of all adult intracranial tumor lesions. These lesions represent a histologically heterogeneous group of tumors. Among these tumors, pineal parenchymal tumors and germ cell tumors (GCT) represent the most frequent types of lesions. According to the new WHO 2021 classification, pineal parenchymal tumors include five distinct histotypes: pineocytoma (PC), pineal parenchymal tumors of intermediate differentiation (PPTID), papillary tumor of the pineal region (PTPR), pinealoblastoma (PB), and desmoplastic myxoid tumor of the pineal region, SMARCB1-mutant; GCTs include germinoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, mixed GCTs. Neuroradiological assessment has a pivotal role in the diagnostic work-up, surgical planning, and follow-up of patients with pineal masses. Surgery can represent the mainstay of treatment, ranging from biopsy to gross total resection, yet pineal region tumors associated with obstructive hydrocephalus may be surgically managed via ventricular internal shunt or endoscopic third ventriculostomy. Radiotherapy remains an essential component of the multidisciplinary treatment approach for most pineal region tumors; however, treatment volumes depend on the histological subtypes, grading, extent of disease, and the combination with chemotherapy. For localized germinoma, the current standard of care is chemotherapy followed by reduced-dose whole ventricular irradiation plus a boost to the primary tumor. For pinealoblastoma patients, postoperative radiation has been associated with higher overall survival. For the other pineal tumors, the role of radiotherapy remains poorly studied and it is usually reserved for aggressive (grade 3) or recurrent tumors. The use of systemic treatments mainly depends on histology and prognostic factors such as residual disease and metastases. For pinealoblastoma patients, chemotherapy protocols are based on various alkylating or platinum-based agents, vincristine, etoposide, cyclophosphamide and are used in association with radiotherapy. About GCTs, their chemosensitivity is well known and is based on cisplatin or carboplatin and may include etoposide, cyclophosphamide, or ifosfamide prior to irradiation. Similar regimens containing platinum derivatives are also used for non-germinomatous GCTs with very encouraging results. However, due to a greater understanding of the biology of the disease's various molecular subtypes, new agents based on targeted therapy are expected in the future. On behalf of the EURACAN domain 10 group, we reviewed the most important and recent developments in histopathological characteristics, neuro-radiological assessments, and treatments for pineal region tumors.
Keywords: EURACAN; pineal region tumors; pinealoblastoma; rare tumors.
Conflict of interest statement
G.L. declares funding for a consulting or advisory role from Bayer, AbbVie, Orbus Therapeutics, BrainFarm, Health4U, Novartis, and Janssen, and funding for travel from Roche, Bayer, and Ipsen. ET declares funding for a consulting or advisory role from Gliocure, AstraZeneca and funding for travel from Novocure. V.Z. declares funding for a consulting or advisory role from Bristol-Myers Squibb and Merck, speakers’ bureau funding from Bayer, Roche, Bristol-Myers Squibb, Astellas Pharma, Servier, AstraZeneca, and Lilly, and funding for travel and accommodation from Bayer, Roche, and Servier. MW has received research grants from Apogenix and Quercis, and honoraria for lectures or advisory board participation or consulting from Bayer, Medac, Merck (EMD), Nerviano Medical Sciences, Novartis, Orbus, Philogen and y-Mabs; AI declares Research grants from Carthera, Transgene, Sanofi, Air Liquide, Servier, Nutritheragene, advisory board for Leo Pharma, Novocure and Boehringer Ingelheim Int, travel funding from Novocure, Carthera and Leo Pharma outside the submitted work. P.L.P., R.M., M.B., G.M., E.R., G.C. have no conflict of interest to declare.
Figures


Similar articles
-
Histopathology of tumors of the pineal region.Future Oncol. 2010 May;6(5):791-809. doi: 10.2217/fon.10.28. Future Oncol. 2010. PMID: 20465391 Review.
-
Pineal/germ cell tumors and pineal parenchymal tumors.Childs Nerv Syst. 2023 Oct;39(10):2649-2665. doi: 10.1007/s00381-023-06081-1. Epub 2023 Oct 13. Childs Nerv Syst. 2023. PMID: 37831207 Review.
-
Brain and Spinal Tumors Originating from the Germ Line Cells.Adv Exp Med Biol. 2023;1405:421-455. doi: 10.1007/978-3-031-23705-8_16. Adv Exp Med Biol. 2023. PMID: 37452948
-
Pathology of pineal region tumors.J Neurooncol. 2001 Sep;54(3):239-49. doi: 10.1023/a:1012721723387. J Neurooncol. 2001. PMID: 11767290 Review.
-
Consensus guidelines for the management of pineal region tumours for low- and middle-income countries.J Pak Med Assoc. 2024 Mar;74(3 (Supple-3)):S135-S144. doi: 10.47391/JPMA.S3.GNO-16. J Pak Med Assoc. 2024. PMID: 39262074
Cited by
-
Papillary Tumor of the Pineal Region Treated With Surgery and Postoperative Radiotherapy: A Case Report.Cureus. 2025 Jan 25;17(1):e77989. doi: 10.7759/cureus.77989. eCollection 2025 Jan. Cureus. 2025. PMID: 39867506 Free PMC article.
-
SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors.Neuro Oncol. 2024 Dec 5;26(12):2159-2173. doi: 10.1093/neuonc/noae128. Neuro Oncol. 2024. PMID: 39073785 Free PMC article. Review.
-
A rare case of pineal astrocytoma with hemorrhagic changes: Diagnostic and surgical challenges.Radiol Case Rep. 2025 Apr 10;20(6):3153-3158. doi: 10.1016/j.radcr.2025.03.003. eCollection 2025 Jun. Radiol Case Rep. 2025. PMID: 40247959 Free PMC article.
-
Pineal region tumors: prognostic stratification based on magnetic resonance imaging features-a retrospective cohort study.Quant Imaging Med Surg. 2025 Jan 2;15(1):177-188. doi: 10.21037/qims-24-281. Epub 2024 Dec 30. Quant Imaging Med Surg. 2025. PMID: 39839036 Free PMC article.
-
Survival and Malignant Transformation of Pineal Parenchymal Tumors: A 30-Year Retrospective Analysis in a Single-Institution.Brain Tumor Res Treat. 2023 Oct;11(4):254-265. doi: 10.14791/btrt.2023.0033. Brain Tumor Res Treat. 2023. PMID: 37953449 Free PMC article.
References
-
- Palmisciano P., Ogasawara C., Nwagwu C.D., Bin Alamer O., Gupta A.D., Giantini-Larsen A.M., Scalia G., Yu K., Umana G.E., Cohen-Gadol A.A., et al. Metastases in the Pineal Region: A Systematic Review of Clinical Features, Management Strategies, and Survival Outcomes. World Neurosurg. 2022;159:156–167.e2. doi: 10.1016/j.wneu.2022.01.005. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources